Analysis of the effects and biological activity of Quizartinib

Quizartinib (Quizartinib) is a new oral tyrosine kinase inhibitor (TKI), mainly used to target patients with acute myeloid leukemia (AML) with the FLT3-ITD (Fms-like tyrosine kinase 3 internal tandem duplication) mutation. FLT3-ITD mutation is a common driver mutation in AML patients and is closely related to abnormal proliferation, enhanced invasiveness and high risk of relapse of leukemia cells. Quizartinib effectively inhibits the proliferation of leukemia cells and induces apoptosis by highly selectively inhibiting the activity of FLT3 receptor tyrosine kinase and blocking downstream signaling pathways, such as RAS/MAPK and PI3K/AKT. Its strong targeting makes it relatively less toxic to normal hematopoietic cells. This is also the advantage of Quizartinib over traditional chemotherapy drugs in targeted therapy.

In terms of biological activity, quizartinib can bind toFLT3-ITD mutant protein and block its phosphorylation activity, thus inhibiting cell cycle regulation and survival signal transmission. This mechanism can directly affect the proliferation dynamics of tumor cells and shows strong anti-leukemia effects in in vitro and in vivo experiments. In addition, quizartinib can also regulate the expression of angiogenesis and apoptosis-related proteins, further enhancing anti-tumor activity. In clinical studies, this drug is often used for maintenance treatment of patients with relapsed or refractory AML. Used alone or in combination with low-dose chemotherapy, it can improve progression-free survival and reduce the relapse rate.

The pharmacokinetic properties of quizartinib show that it is well absorbed orally and has a long half-life, making it suitable for daily or every other day administration to ensure sustained effective concentration in the body. Its ability to selectively inhibit FLT3-ITD not only reduces non-target cell toxicity but also reduces the risk of severe myelosuppression common in traditional chemotherapy. At the same time, quizartinib also shows good synergy when combined with other drugs, such as azacitidine, normethotrexate or low-dose chemotherapy, which can further enhance the anti-AML efficacy and provide new strategies for multi-line treatment.

Reference materials:https://go.drugbank.com/drugs/DB12874